The interleukin (IL)-17/IL-23 axis is an important pro-inflammatory pathway in rheumatoid arthritis (RA). IL-23 maintains CD4 þ T-helper 17 (Th 17 ) cells, whereas IL-12 negates IL-17A production by promoting Th 1 -cell differentiation. We sought evidence for any effect of polymorphisms within the interleukin-23 receptor (IL-23R), IL-12 or IL-21 genes on serum cytokine concentrations in 81 patients with RA. Serum cytokines were measured using bead-based multiplex assays. Targeted cytokines were detected in up to 66% of samples. A subgroup of 48 patients had detectable serum IL-17A. Within this subgroup, patients, homozygous for the IL-23R rs11209026 major allele had significantly higher serum IL-17A concentrations compared with patients with the minor allele (394.51 ± 529.72 pg ml --1 vs 176.11 ± 277.32 pg ml --1 ; P ¼ 0.017). There was no significant difference in any of the cytokine concentrations examined in patients positive for the minor allele vs homozygosity for the major allele of IL-12B rs3213337, IL-12Bpro rs17860508 and IL-21 rs6822844. Our results suggest the IL-23R Arg381Gln substitution may influence serum IL-17A concentrations. In patients with the 381Gln allele higher IL-23 concentrations may be needed to produce similar IL-17A concentrations to those in patients with the 381Arg allele. This suggests altered IL-23R function in patients with the minor allele and warrants further functional studies.
INTRODUCTION

Interleukin (IL)-17A is the prototypic cytokine produced by CD4
þ T-helper 17 (Th) 17 cells. Experimental data from murine studies suggested that the capacity of CD4
þ Th 17 cells and IL-17A to cause T-cell-mediated inflammation and autoimmune disease could explain pathogenic features of autoimmunity not accounted for by the CD4 þ Th 1 and Th 2 paradigm. In particular, mice genetically deficient in the Th 1 signature cytokine, interferon-g are not protected, and actually exhibited enhanced susceptibility to autoimmune disease. 1 --3 In line with this data, IL-17A, has emerged as a key pro-inflammatory cytokine in rheumatoid arthritis (RA), supported by recent clinical studies that indicate Th 17 cells respond to relevant arthritogenic peptides 4 and neutralization of IL-17A will improve signs and symptoms of clinical disease. 5 However, IL-17A is only expressed in a subset of synovia from patients with RA, suggesting it is more likely an amplifier of synovial inflammation in those patients where it is present rather than an absolute requirement in RA. 6 The production of IL-17A from human Th 17 cells is influenced by several cytokines, but the two most significant appear to be IL-12 and IL-23. 6 IL-12 acts to inhibit IL-17A production by favoring the development of Th 1 cells over Th 17 cells. IL-12 consists of two subunits, p35 and p40, encoded by the IL-12A and IL-12B genes, respectively. A 4-bp insertion in the promoter region of IL-12B (IL-12Bpro; rs17860508) has been shown to decrease the amount of IL-12p70 secreted by human monocyte-derived dendritic cells in vitro. 7 A further polymorphism present within the 3 0 UTR of the IL-12B gene (rs3212227), reflecting an A to C nucleotide substitution at position 1188, has been associated with various autoimmune diseases including type 1 diabetes, 8 multiple sclerosis 9 and psoriasis. 10 The IL-12 p40 subunit can also form heterodimers with p19 resulting in formation of IL-23. IL-23 is a key player in IL-17A-mediated inflammation, maintaining the expansion of human Th 17 cells. This function of IL-23 is mediated by the IL-23 receptor (IL-23R), which is composed of two subunits; the IL-23R subunit, encoded by the IL-23R gene, and the IL-12Rb1 subunit. Within the IL-23R gene, a single-nucleotide polymorphism (SNP) rs11209026 results in an Arg to Gln substitution at position 381 (IL-23R 381Gln). 11 This SNP has strong associations with Crohn's disease 12 and psoriasis, 10, 13 but there is no association with RA. 14 Recent evidence suggests that the function of this IL-23R variant might be affected with direct implications for serum cytokine concentrations and consequent effects on dependent cytokines. 15 Along with IL-17A, activated Th 17 cells also produce IL-17F, IL-21, IL-22 and IL-26. In vivo evidence suggests that each of these cytokines makes a contribution to the pathogenic character of the Th 17 cells involved in experimental arthritis. In vitro Th 17 cytokines induce and act in synergy with TNF-a and IL-1b to promote joint inflammation or independently to induce receptor activator of NF-kB ligand (RANK-L) expression resulting in osteoclastogenesis and bone destruction. 16 Alterations in the concentrations of these cytokines may therefore have wide-reaching effects on inflammation and joint damage in RA. IL-21 is a pleiotropic inflammatory cytokine and the intergenic SNP rs6822844 (G to T substitution) has been associated with several autoimmune diseases including RA. 17 Given the role of IL-23 and IL-12 in Th 17 cell development, we hypothesized that genetic variations in IL-23R and IL-12 would influence the cytokine profile of Th 17 cells. The aim of this study was to investigate the relationships between genetic variants in IL-23R, IL-12B and IL-21 and related serum cytokine concentrations.
RESULTS
Patients and genotypes
Patient demographics are outlined in Table 1 . No patients were receiving anti-TNF therapy. The SNPs examined (identified by reference SNP (rs) number) were genotypically defined as major or minor (homozygous or heterozygous for the mutant allele) as follows: IL-23R rs11209026 major 381Arg/Arg, minor 381 Arg/Gln or Gln/Gln; IL-12 rs3212227 major AA, minor AC or CC; IL-12Bpro rs178600508 major IL-12Bpro-1 (1 --1), minor IL-12Bpro-2 (1 --2 or 2 --2); IL-21 rs6822844 major G/G, minor G/T or T/T. Table 2 shows the number of patients with each genotype. Three of the SNP's were in Hardy --Weinberg (H --W) equilibrium (rs11209026, P ¼ 0.07; rs3212227, P ¼ 0.11; IL-12Bpro, P ¼ 0.03). However, the IL-21 SNP rs6822844 was strongly out of H --W equilibrium (P ¼ 8 Â 10
À5
). This is most likely to be due to the small sample size, as we have separately shown rs6822844 to be in H --W equilibrium in a larger New Zealand RA sample set (n ¼ 834, P ¼ 0.12). 18 Serum cytokine concentrations There was wide variation in individual cytokine concentrations ( Figure 1 ). In 18 patients, none of the cytokines examined were detectable. Of the 36 patients with detectable IL-1b, 12 had little or no detectable amounts of the other cytokines. There were positive correlations between all cytokines measured with the exception of IL-1b (Table 3) .
Influence of IL-23R, IL-12 or IL-21 genotype on serum cytokine concentrations In the group as a whole, there was no significant difference in serum concentrations of any of the cytokines examined in patients with the IL-23R minor (homozygous or heterozygous) genotype as compared with the major genotype. However, in the 48 patients who had detectable IL-17A, patients positive for the minor IL-23R (381Gln) allele had significantly lower IL-17A concentrations as compared with patients homozygous for the IL-23R major 381Arg allele (176.11 ± 277.32 pg ml --1 vs 394.51 ± 529.72 pg ml --1 ; P ¼ 0.017). There was no significant difference in IL-21 or IL-22 concentrations in serum from patients with the IL-23R major vs minor genotypes (Table 4) . Consistent with these observations, among all the patients (n ¼ 81), we found no significant association between the presence of the IL23R 381Gln allele or 381Arg allele per se and serum concentrations for any cytokine (for example, IL-17A: regression coefficient (b) ¼ --88.8, P ¼ 0.26; and data not shown). When analysis was restricted to the 48 patients with detectable IL-17A, there was a trend towards lower IL-17A concentrations and the presence of the IL23R 381Gln allele
There was no significant difference in serum cytokine concentrations between patients with the major or minor IL-12B rs3212227 genotypes, the major or minor IL-12Bpro genotypes or the major or minor IL-21 rs6822844 genotypes, nor any relationship between the minor allele and cytokine concentrations (data not shown).
Influence of IL-23R, IL-12 or IL-21 genotype on the inter-relationships between serum cytokines There was a strong positive correlation between serum IL-17A and IL-23 concentrations in patients homozygous for the IL-23R major allele (r ¼ 0.503, P ¼ 0.0003), which was not present in the group of patients with the IL-23R minor allele (homozygous or heterozygous) (r ¼ 0.32, P ¼ 0.071). Similarly, there was a significant positive correlation between serum IL-12 and IL-23 concentrations in patients homozygous for the IL-23R major allele (r ¼ 0.306, P ¼ 0.036), which was not evident in patients with the IL-23R minor allele (homozygous or heterozygous) (r ¼ 0.21, P ¼ 0.24). However, we found no significant difference between the correlations.
Although there was a strong positive correlation between serum IL-23 and TNF-a concentrations (Po0.0001), only a minority of patients had detectable IL-23 and/or TNF-a. In those patients with undetectable TNF-a, IL-23 concentrations were low. However, when TNF-a was present, IL-23 was present in higher concentrations (Po0.05) ( Figure 2 ). This pattern was not significantly affected by the IL-23R genotype. Similar patterns were observed for the relationships between serum concentrations of IL-17A or IL-22 in presence or absence of IL-12. When IL-12 was undetectable, IL-17A and IL-22 concentrations were low, but in the presence of IL-12, both IL-17A and IL-22 were present in significantly higher concentrations (Po0.05 for both).
There were significant correlations between IL-21 and IL-12, IL-17A and IL-22 in patients with the IL-21 rs6822844 major allele (all Po0.0001). However, this correlation was not observed in patients positive for the IL-21 rs6822844 minor allele. Again, we found no difference between the correlations.
Relationship between C-reactive protein (CRP), genotype and serum cytokine concentrations There was a statistically significant correlation between CRP and serum concentrations of IL-12 (P ¼ 0.008), IL-17A (P ¼ 0.047), and 
11 (14) Abbreviations: IL, interleukin; RA, rheumatoid arthritis. The IL-23R SNP, rs11209026, has been associated with inflammatory bowel disease, but to date it has not been shown to be associated with RA. This SNP results in a substitution of Arg with Gln within the IL23R-binding domain for the JAK2 kinase, 13 and thus has the potential to alter downstream signaling events and responses to IL-23. We detected serum IL-17A in B59% of patients with RA. This is in keeping with other studies that report the presence of IL-17A in only a proportion of patients. 20, 21 The reason why IL-17A is only present in a subgroup of patients remains unclear. However, RA is a heterogeneous disease and the presence of IL-17A clearly defines a specific subgroup of patients who appear to have more aggressive disease, with evidence that the presence of IL-17 results in more joint erosion 22 and may predict vascular function in RA. 20 As such, we undertook our analysis in the subgroup of patients with detectable levels of IL-17A. Within this subgroup, those patients homozygous for the IL-23R 381Arg major allele had significantly higher IL-17A concentrations as compared with patients positive for the IL-23R Arg381Gln minor allele. This suggests that IL-23R function is altered by the polymorphism resulting in decreased IL-17A 15 Furthermore, recent functional data is in keeping with our results with inhibition of IL-23-mediated IL-17A production in carriers of the minor allele. 23 Despite the observed difference in IL-17A in the different IL-23R genotypes, there was no alteration in IL-21 or IL-22 serum concentrations in patients with the major or minor IL-23R genotype. Nor was there any significant difference in the concentrations of the other non-Th 17 cytokines examined associated with the IL23R SNP. Recent evidence suggests that there is differential regulation of IL-21, IL-22 and IL-17A production. In a murine study, Mus et al. 24 reported that IL-23 promoted Th 17 differentiation and was required for IL-17A and IL-22 production, but not IL-21 production. IL-12 and IL-23 have also been reported to have an important role in induction of IL-22 production from naïve human CD4 þ T cells. 25 Another potential explanation for the observed difference in our results is the production of these cytokines by different cell types also under differential cytokine control. As with IL-17A, IL-22 expression is not restricted to Th 17 cells; gd T cells, NKT cells and NK cells can all express this cytokine after activation. 26 Lymphoid tissue-inducer cells also constitutively express IL-22 that can be further induced by IL-23 stimulation. 27, 28 IL-23 and IL-12 share a common subunit, and can both influence IL-17A production. Polymorphisms in IL-12 therefore have the potential to alter cytokine concentrations. Indeed, IL-12Bpro-1 has been shown to reduce IL-12p70 secretion from human monocyte-derived dendritic cells in vitro.
7 Despite this, we found no evidence to suggest that the IL-12 polymorphisms IL12Bpro or rs3212227 affected serum concentrations of any of the cytokines we examined. This may reflect production of IL-17A and related cytokines from other cellular sources that are not influenced by IL-12, that the IL-12 polymorphisms examined do not have a functional effect on Th 17 cytokine production or that the presence of cytokines that enhance Th 17 cytokine production dominate in patients with RA. It is also possible that our sample size was too small to detect a small effect of genotype on serum cytokine levels.
Of note, for each cytokine, a third or more of patients had undetectable concentrations. In addition, the cytokine profile varied for each individual, ranging from an absence of all seven cytokines, to presence of all seven cytokines. Similar patterns of cytokine expression have been reported previously. 29 The concentrations of the cytokines measured in our study are consistent with those reported in other studies. 30, 31 Although IL1b has been shown to correlate with RA disease severity, 32 our data suggest it is largely independent of the other cytokines measured, and tends to be present in large amounts or not at all. This most likely reflects a different inflammatory pathway dominating in these patients. This variability in both the profile of cytokines present and the individual cytokine concentrations reflects the well-recognized heterogeneity of RA.
As expected, we have shown a positive correlation between serum IL-23 and IL-17A. However, there was also a positive correlation between IL-12 and IL-17A, IL-21, IL-22, IL-23 and TNF-a. These data are in keeping with the role of IL-23 in maintaining the Th 17 cell line and cytokine production. Although IL-12 has been reported to have a role in inhibiting IL-17A production, the positive correlation may be explained by positive feedback loops between these interacting cytokines. We also observed a relationship between IL-23 and TNF-a such that serum IL-23 concentrations were significantly higher when TNF-a was present. It is likely that higher IL-23 concentrations indicate the presence of more Th 17 cells, which in turn contribute to the levels of TNF-a. Similar patterns were observed for both IL-17A and IL-22 in the presence or absence of IL-12. Although IL-12 opposes Th17 differentiation and IL-17A production, these results may not be a result of a direct link, but rather indicate a more inflamed and active immune system overall.
Of note, we have also shown detectable IL-21 and IL-22 in B50% of serum samples. Although IL-21R has been reported to be expressed in RA synovial fibroblasts and macrophages, no IL-21 was present by PCR in RA synovium or synovial fluid. 33 In another smaller study, IL-21 mRNA was detectable in cultured RA synovial cells but IL-21 protein was not detectable. 34 Recent evidence suggests a significant association between plasma levels of IL-21 and disease activity in patients with early RA, but showed no difference from controls in established disease. 35 Thus, the mean IL-21 concentration in our RA cohort with established disease (522.22 ± 967.23 pg ml --1 , range 0 --5000 pg ml --1 ) appears to be higher than concentrations reported, 35 and in healthy donors at B50 pg ml --1 . 36 Despite these anomalies, the presence of IL-21 in the systemic circulation and absence within the joint is of interest. RA peripheral blood and synovial T cells stimulated with anti-CD3 and IL-21 produce more TNF-a and interferon-g than T-cells from healthy controls. 37 Furthermore, inhibition of IL-21 results in reduced TNF-a production. 34 Taken together with evidence that IL-21 acts in an autocrine fashion upon human Th 17 cells in RA, 38 these data suggest that IL-21 makes a substantial contribution to the systemic inflammatory process in RA through upregulation of T-cell cytokines. Furthermore, it is important to bear in mind that rs6822844, within the IL-21 locus, is associated with RA. 18 This may also explain the association between rs6822844 and CRP concentration that we observed in the current study.
IL-22 has both proinflammatory and protective properties; this dichotomy is not yet fully understood. In experimental models of RA, IL-22 is proinflammatory. Thus, IL-22-deficient mice have a lower incidence of collagen-induced disease and less pannus formation. 39 IL-22 and IL-22R1 have been shown in RA synovial fibroblasts and macrophages and recombinant IL-22-induced synovial fibroblast proliferation and MCP-1 expression. 40 The significant association we observed between serum concentrations of IL-22 and CRP suggests this cytokine is associated with increased inflammatory activity. This is consistent with a recent report that links IL-22 serum concentrations with radiographic progression in RA. 41 In summary, our results suggest that the IL-23R Arg381Gln substitution may alter IL-23R function, thereby influencing serum IL-17A concentrations. In comparison, polymorphisms in the IL-12 Figure 2 . Relationship between serum IL-23 concentrations in the presence or absence of TNF-a for patients with either IL-23R major or minor genotype. *Po0.05, **Po0.01. gene appear to have little influence on serum cytokine levels. There is clearly an impact on mechanisms dictating the degree of systemic inflammation in RA. Whether similar effects occur in the synovium remains to be determined.
MATERIALS AND METHODS
Ethical approval was obtained from the Multi-Region Ethics Committee, Wellington, New Zealand. All patients gave written informed consent, obtained according to the Declaration of Helsinki. A total of 81 patients with RA as defined by the 1987 American Rheumatism Association criteria 42 were recruited. DNA was extracted from white blood cells by a GuHCl-based method. Serum was collected and stored at À80 1C. Rheumatoid factor and anti-cyclic citrullinated peptide antibody status were obtained. CRP was measured as a marker of disease activity.
Cytokine assays
Serum concentrations of IL-1b, IL-23, IL-17A, IL-12, IL-21, IL-22 and TNF-a were determined using commercial FlowCytomix Simplex kits (Bender MedSystems, Vienna, Austria) or cytometric bead array assays (Becton Dickinson systems, BD BioSciences, San Jose, CA, USA). As some beads were incompatible, the measurements were done in two groups, multiplexing for IL-1b, IL-23 and TNF-a together in the first instance, and then for IL-12, IL-17A and IL-22 in a second series of multiplex assays. For IL-23, both p19 and p40 subunits were detected on the bead. Sensitivity of the beads, identifying a positive sample, ranged from 1.5 --43.3 pg ml --1 . Serum IL-21 concentrations were also determined using cytometric bead array assays. For all assays, samples were prepared in 96-well filter plates as recommended by the manufacturers. Data was collected using a 
Genotyping
Genotyping of IL-23R rs11209026 was performed using a TaqMan assay (C_1272298_10; Applied Biosystems, Foster City, CA, USA). The IL-12B SNP rs3212227 was genotyped by PCR-RFLP assays. The primers were 5 0 -GA TATCTTTGCTGTATTTGTATAGTT-3 0 and 5 0 -AATATTTAAATAGCATGAAGGC-3 0 , which generated a 118-bp fragment. This PCR-RFLP assay included 4 mM MgCl 2 and an annealing temperature of 53 1C. The fragment was then digested by TaqI (New England BioLabs). The major A allele resulted in a single 118-bp fragment and the minor C allele produced 2 fragments of 92 and 26 bp. The IL-12pro SNP was identified using the allele-specific forward primers IL-12B5-8 (5 0 -TGT CTC CGA GAG AGG CTC TAA-3 0 ) or IL-12B5-10 (5 0 -TGT CTC CGA GAG AGG GCT GT-3 0 ), with a common primer IL-12B 3-5 (5 0 -TGG AGG AAG TGG TTC TCG TAC-3 0 ). This PCR gave two products of different sizes, designated IL-12B5-8 (long 154bp, major allele) and IL-12B5-10 (short 150bp, minor allele). Genotyping of IL-21 rs6822844 was performed using a TaqMan assay (C_28983601_10) (Applied Biosystems).
Statistical analysis
